FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3161453886> ?p ?o ?g. }

• W3161453886 endingPage "4709" @default.
• W3161453886 startingPage "4700" @default.
• W3161453886 abstract "Ceralasertib is a potent and selective oral inhibitor of the serine/threonine protein kinase ataxia telangiectasia and Rad3-related (ATR) protein.Eligible patients with solid tumors, enriched for melanoma, received ceralasertib in combination with a fixed dose of paclitaxel (80 mg/m2 on D1, D8, D15) in 28-day cycles. The dose of ceralasertib was escalated to reach an MTD in a rolling 6 design. The starting dose of ceralasertib was 40 mg QD. Fifty-seven patients (33 patients with melanoma who failed prior PD1/L1 treatment) were enrolled in 7 dose cohorts ranging from 40 mg QD to 240 mg BD plus weekly paclitaxel.The RP2D was established as ceralasertib 240 mg BD days 1-14 plus paclitaxel 80 mg/m2 on D1, D8, D15 every 28 days. The most common toxicities were neutropenia (n = 39, 68%), anemia (n = 25, 44%), and thrombocytopenia (n = 21, 37%). In the full analysis set of 57 patients, the overall response rate (ORR) was 22.6% (95% CI, 12.5-35.3). In 33 patients with melanoma, resistant to prior anti-PD1 therapy, the ORR was 33.3% (95% CI, 18.0-51.8). In the melanoma subset, the mPFS was 3.6 months (95% CI, 2.0-5.8), the median duration of response was 9.9 months (95% CI, 3.7-23.2), and the mOS was 7.4 months (95% CI, 5.7-11.9).Ceralasertib in combination with paclitaxel was well tolerated in patients with advanced malignancies and showed evidence of antitumor activity. Durable responses were observed in patients with advanced cutaneous, acral, and mucosal melanoma resistant to anti-PD1/L1 treatment.See related commentary by Ashworth, p. 4667." @default.
• W3161453886 created "2021-05-24" @default.
• W3161453886 creator A5005933314 @default.
• W3161453886 creator A5010584350 @default.
• W3161453886 creator A5013311116 @default.
• W3161453886 creator A5013931444 @default.
• W3161453886 creator A5015598872 @default.
• W3161453886 creator A5019406140 @default.
• W3161453886 creator A5020083935 @default.
• W3161453886 creator A5026351538 @default.
• W3161453886 creator A5028617609 @default.
• W3161453886 creator A5030995134 @default.
• W3161453886 creator A5033008477 @default.
• W3161453886 creator A5033310499 @default.
• W3161453886 creator A5034241161 @default.
• W3161453886 creator A5035341984 @default.
• W3161453886 creator A5045587524 @default.
• W3161453886 creator A5055431215 @default.
• W3161453886 creator A5057146015 @default.
• W3161453886 creator A5065244228 @default.
• W3161453886 creator A5079442967 @default.
• W3161453886 creator A5082781519 @default.
• W3161453886 date "2021-05-11" @default.
• W3161453886 modified "2023-10-09" @default.
• W3161453886 title "Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer" @default.
• W3161453886 cites W1935885922 @default.
• W3161453886 cites W1942954494 @default.
• W3161453886 cites W1968965382 @default.
• W3161453886 cites W2019607817 @default.
• W3161453886 cites W2024231564 @default.
• W3161453886 cites W2039707521 @default.
• W3161453886 cites W2040860750 @default.
• W3161453886 cites W2075927156 @default.
• W3161453886 cites W2079853060 @default.
• W3161453886 cites W2081938650 @default.
• W3161453886 cites W2109637301 @default.
• W3161453886 cites W2111237964 @default.
• W3161453886 cites W2113122060 @default.
• W3161453886 cites W2128941584 @default.
• W3161453886 cites W2136925048 @default.
• W3161453886 cites W2145264022 @default.
• W3161453886 cites W2151918127 @default.
• W3161453886 cites W2153466677 @default.
• W3161453886 cites W2160738354 @default.
• W3161453886 cites W2160981405 @default.
• W3161453886 cites W2170973522 @default.
• W3161453886 cites W2408787182 @default.
• W3161453886 cites W2527905628 @default.
• W3161453886 cites W2559890484 @default.
• W3161453886 cites W2580220347 @default.
• W3161453886 cites W2587333476 @default.
• W3161453886 cites W2605683323 @default.
• W3161453886 cites W2627067328 @default.
• W3161453886 cites W2770128744 @default.
• W3161453886 cites W2788431960 @default.
• W3161453886 cites W2792850129 @default.
• W3161453886 cites W2805040559 @default.
• W3161453886 cites W2897726163 @default.
• W3161453886 cites W2899040421 @default.
• W3161453886 cites W2902324525 @default.
• W3161453886 cites W2911653212 @default.
• W3161453886 cites W2915645504 @default.
• W3161453886 cites W2958034733 @default.
• W3161453886 cites W2978929492 @default.
• W3161453886 cites W3014748351 @default.
• W3161453886 doi "https://doi.org/10.1158/1078-0432.ccr-21-0251" @default.
• W3161453886 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33975862" @default.
• W3161453886 hasPublicationYear "2021" @default.
• W3161453886 type Work @default.
• W3161453886 sameAs 3161453886 @default.
• W3161453886 citedByCount "41" @default.
• W3161453886 countsByYear W31614538862021 @default.
• W3161453886 countsByYear W31614538862022 @default.
• W3161453886 countsByYear W31614538862023 @default.
• W3161453886 crossrefType "journal-article" @default.
• W3161453886 hasAuthorship W3161453886A5005933314 @default.
• W3161453886 hasAuthorship W3161453886A5010584350 @default.
• W3161453886 hasAuthorship W3161453886A5013311116 @default.
• W3161453886 hasAuthorship W3161453886A5013931444 @default.
• W3161453886 hasAuthorship W3161453886A5015598872 @default.
• W3161453886 hasAuthorship W3161453886A5019406140 @default.
• W3161453886 hasAuthorship W3161453886A5020083935 @default.
• W3161453886 hasAuthorship W3161453886A5026351538 @default.
• W3161453886 hasAuthorship W3161453886A5028617609 @default.
• W3161453886 hasAuthorship W3161453886A5030995134 @default.
• W3161453886 hasAuthorship W3161453886A5033008477 @default.
• W3161453886 hasAuthorship W3161453886A5033310499 @default.
• W3161453886 hasAuthorship W3161453886A5034241161 @default.
• W3161453886 hasAuthorship W3161453886A5035341984 @default.
• W3161453886 hasAuthorship W3161453886A5045587524 @default.
• W3161453886 hasAuthorship W3161453886A5055431215 @default.
• W3161453886 hasAuthorship W3161453886A5057146015 @default.
• W3161453886 hasAuthorship W3161453886A5065244228 @default.
• W3161453886 hasAuthorship W3161453886A5079442967 @default.
• W3161453886 hasAuthorship W3161453886A5082781519 @default.
• W3161453886 hasBestOaLocation W31614538861 @default.
• W3161453886 hasConcept C121332964 @default.
• W3161453886 hasConcept C121608353 @default.

• next